<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24379" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Liver Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bashir</surname>
            <given-names>Anam</given-names>
          </name>
          <aff>West Virginia University-Charleston/CAMC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hoilat</surname>
            <given-names>Gilles J.</given-names>
          </name>
          <aff>University of Iowa Hospital &#x00026; Clinics</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sarwal</surname>
            <given-names>Parul</given-names>
          </name>
          <aff>Saint Vincent Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mehta</surname>
            <given-names>Dhruv</given-names>
          </name>
          <aff>Westchester MC at NY Medical College</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anam Bashir declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gilles Hoilat declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Parul Sarwal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dhruv Mehta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24379.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>One of the most important causes of liver dysfunction is drug-induced liver injury (DILI) which can lead to a wide spectrum of symptoms ranging from mild non-specific symptoms like asymptomatic transaminitis, acute hepatitis, chronic hepatitis, cholestasis to liver failure. It can be caused by a multitude of prescription drugs, herbal and dietary supplements and commonly leads to withdrawal of the drug from the market. This activity reviews the cause of liver toxicity, the pathophysiology, presentation and highlights the role of the interprofessional team in the management of these patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the drugs that can cause liver toxicity.</p></list-item><list-item><p>Describe the pathophysiology of drug induced liver damage.</p></list-item><list-item><p>Summarize the evaluation of patients with drug induced liver toxicity.</p></list-item><list-item><p>Outline the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by liver toxicity</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24379&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24379">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24379.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>One of the most important causes of liver dysfunction is drug-induced liver injury (DILI) which can lead to a wide spectrum of symptoms ranging from mild non-specific symptoms like asymptomatic transaminitis, acute hepatitis, chronic hepatitis, cholestasis to liver failure.<xref ref-type="bibr" rid="article-24379.r1">[1]</xref>&#x000a0;It can be caused by a multitude of prescription drugs, herbal and dietary supplements and&#x000a0;commonly leads to withdrawal of the drug from the market.<xref ref-type="bibr" rid="article-24379.r2">[2]</xref></p>
      </sec>
      <sec id="article-24379.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>There are many classes of drugs causing drug-induced liver injury including nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infective drugs&#x000a0;(anti-tubercular drugs), anti-cancer drugs, hormonal drugs, immunosuppressive agents, sedative, and neuropsychiatric drugs.<xref ref-type="bibr" rid="article-24379.r3">[3]</xref>&#x000a0;The most common drug implicated in&#x000a0;drug-induced liver injury&#x000a0;is acetaminophen.<xref ref-type="bibr" rid="article-24379.r4">[4]</xref>&#x000a0;Antibiotics are the class of drugs most commonly causing liver toxicity,<xref ref-type="bibr" rid="article-24379.r5">[5]</xref>&#x000a0;and amoxicillin-clavulanate stands out as the most common drug in this class.<xref ref-type="bibr" rid="article-24379.r6">[6]</xref>&#x000a0;Additionally, herbal supplements cause a variety of symptoms, but their usage remains under-reported.<xref ref-type="bibr" rid="article-24379.r7">[7]</xref>&#x000a0;The NIH LiverTox website is an online resource that provides comprehensive information about&#x000a0;drug-induced liver injury&#x000a0;caused by prescription drugs and dietary and herbal supplements.</p>
      </sec>
      <sec id="article-24379.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Drug-induced liver injury is the most common cause of acute liver failure (ALF) in the United States and Europe<xref ref-type="bibr" rid="article-24379.r8">[8]</xref>&#x000a0;and accounts for 20% to 40% of all instances of fulminant hepatic failure.<xref ref-type="bibr" rid="article-24379.r9">[9]</xref>&#x000a0;Although the incidence of&#x000a0;drug-induced liver injury&#x000a0;has been reported to be as low as 1 in 10,000 to 100,000,<xref ref-type="bibr" rid="article-24379.r10">[10]</xref>&#x000a0;the absolute incidence of&#x000a0;drug-induced liver injury&#x000a0;is still unknown as many cases are missed or underreported.<xref ref-type="bibr" rid="article-24379.r11">[11]</xref>&#x000a0;It is also difficult to confidently ascribe hepatic injury to a drug because currently,&#x000a0;there are no universally accepted guidelines to assess&#x000a0;drug-induced liver injury.&#x000a0;Drug-Induced Liver Injury Network has been established&#x000a0;in the United States since 2003 to understand the causes, risk factors, and outcomes of&#x000a0;drug-induced liver injury&#x000a0;by collecting and analyzing suspected cases.<xref ref-type="bibr" rid="article-24379.r12">[12]</xref>&#x000a0;Multiple risk factors like old age, female gender, chronic alcoholism, and pregnancy have been described in the literature&#x000a0;to cause an increased risk of&#x000a0;drug-induced liver injury. However, some studies have revealed these factors do&#x000a0;pose a higher risk to specific drugs and not all-cause liver toxicity (liver toxicity caused by all drugs). For example, children are at an increased risk of liver toxicity caused by valproate and are more prone to&#x000a0;Reye syndrome with aspirin. But with increasing age, the risk of toxicity increases with drugs like amoxicillin-clavulanate.<xref ref-type="bibr" rid="article-24379.r13">[13]</xref>&#x000a0;Some HLA types (human leukocyte antigen) serotypes have been identified as risk factors for&#x000a0;drug-induced liver injury.<xref ref-type="bibr" rid="article-24379.r14">[14]</xref></p>
      </sec>
      <sec id="article-24379.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Liver&#x000a0;damage can be hepatocellular, cholestatic, or mixed (includes features of both).<xref ref-type="bibr" rid="article-24379.r6">[6]</xref>&#x000a0;Cholestatic damage commonly occurs due to the drug or the drug metabolite. They inhibit hepatobiliary transporter systems which are&#x000a0;essential for bile formation and secretion of cholephilic substances and xenobiotics.<xref ref-type="bibr" rid="article-24379.r15">[15]</xref>&#x000a0;Hepatocellular occurs through multiple pathways including direct hepatotoxicity, and innate and adaptive immune responses.<xref ref-type="bibr" rid="article-24379.r8">[8]</xref>&#x000a0;Drug-induced liver injury&#x000a0;can be dose-dependent/intrinsic, and on most occasions, it is dose-independent/idiosyncratic. Acetaminophen usually causes&#x000a0;drug-induced liver injury&#x000a0;in a dose-dependent&#x000a0;fashion. Most other drugs cause a dose-independent pattern of hepatotoxicity.<xref ref-type="bibr" rid="article-24379.r16">[16]</xref></p>
      </sec>
      <sec id="article-24379.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Similar to the clinical patterns,&#x000a0;drug-induced liver injury&#x000a0;can present in different histopathologic manifestations. It can cause acute and chronic hepatocellular pattern of injury. Acute hepatocellular usually resembles that of acute hepatitis while chronic hepatocellular&#x000a0;patterns usually resemble that of chronic hepatitis, autoimmune hepatitis, fibrosis, and cirrhosis. A cholestatic pattern shows cholestasis. Some cause steatosis and steatohepatitis pattern resembling that of alcoholic&#x000a0;fatty liver disease or nonalcoholic fatty liver disease. It can also present as granulomas, various vascular injury patterns, cytoplasmic inclusions, lipidosis and pigments, and drug-induced&#x000a0;neoplasms.<xref ref-type="bibr" rid="article-24379.r16">[16]</xref></p>
      </sec>
      <sec id="article-24379.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Some patients present with fatigue, decreased appetite, aversion to oily food, epigastric discomfort and tender liver. Patients with cholestatic type can present with jaundice, light colored faeces and pruritis. Occasionally, they can also have allergic manifestations like fever, rash and aching in joints.<xref ref-type="bibr" rid="article-24379.r3">[3]</xref></p>
      </sec>
      <sec id="article-24379.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>In most cases,&#x000a0;drug-induced liver injury&#x000a0;may cause mild to moderate elevation of liver tests, but in rare cases, it can lead to fatal outcomes.<xref ref-type="bibr" rid="article-24379.r17">[17]</xref>&#x000a0;It can cause elevation of liver enzymes including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), and total bilirubin.<xref ref-type="bibr" rid="article-24379.r8">[8]</xref>&#x000a0;However, there is currently&#x000a0;no single test that can predict DILI.<xref ref-type="bibr" rid="article-24379.r8">[8]</xref>&#x000a0;Patients with allergic manifestation can have eosinophilia and elevated autoantibodies.<xref ref-type="bibr" rid="article-24379.r18">[18]</xref>&#x000a0;Chronic,&#x000a0;drug-induced liver injury&#x000a0;can present with different manifestations including chronic hepatitis, liver fibrosis, cirrhosis.<xref ref-type="bibr" rid="article-24379.r3">[3]</xref>&#x000a0;Elevated serum bilirubin, low albumin, and blood coagulation defects signify severe liver damage.<xref ref-type="bibr" rid="article-24379.r3">[3]</xref>&#x000a0;Also, hepatocellular&#x000a0;drug-induced liver injury&#x000a0;causes more elevation of ALT&#x000a0;as compared to ALP and&#x000a0;vice-versa in the case of cholestatic.<xref ref-type="bibr" rid="article-24379.r18">[18]</xref>&#x000a0;In 2011, the International Serious Adverse Events Consortium (iSAEC) recommended&#x000a0;modified biochemical criteria for identification of&#x000a0;drug-induced liver injury&#x000a0;as reaching any of the following items<xref ref-type="bibr" rid="article-24379.r19">[19]</xref>:</p>
        <list list-type="order">
          <list-item>
            <p>Alanine transferase greater than or equal to 5 ULN</p>
          </list-item>
          <list-item>
            <p>Alkaline Phosphatase greater than or equal to 2 ULN, especially in patients with elevated 5'-nucleotidase or GGT, and without bone-diseases-related ALP elevation</p>
          </list-item>
          <list-item>
            <p>Alanine transferase greater than or equal to 3 ULN and total bilirubin greater than or equal to 2 ULN</p>
          </list-item>
        </list>
        <p>This&#x000a0;recommendation was&#x000a0;given&#x000a0;to avoid unnecessary drug withdrawals. But it is difficult to&#x000a0;confidently ascribe&#x000a0;at times&#x000a0;whether it is&#x000a0;drug-induced liver injury&#x000a0;or aggravation of a&#x000a0;pre-existing liver injury.<xref ref-type="bibr" rid="article-24379.r3">[3]</xref>&#x000a0;Generally, the elevation of liver tests can be attributed to&#x000a0;drug-induced liver injury&#x000a0;when there is preceding history of drug exposure, discontinuation of the drug leads to improvement in liver injury, recurrence on rechallenge and the drug does have a history of causing drug-induced liver injury&#x000a0;in other patients.<xref ref-type="bibr" rid="article-24379.r20">[20]</xref></p>
      </sec>
      <sec id="article-24379.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Discontinuing the suspected drug is the first step in the management of&#x000a0;drug-induced liver injury.<xref ref-type="bibr" rid="article-24379.r3">[3]</xref>&#x000a0;N-acetylcysteine is the antidote for acetaminophen poisoning. However, intravenous N- acetylcysteine has been shown to improve survival with non-acetaminophen-related acute liver failure.<xref ref-type="bibr" rid="article-24379.r21">[21]</xref>&#x000a0;Carnitine has been used in valproate injury. Steroids have been proposed as a therapeutic option for liver injury but have not been well studied.<xref ref-type="bibr" rid="article-24379.r22">[22]</xref>&#x000a0;Currently, glucocorticoids are used for immune-mediated&#x000a0;drug-induced liver injury.<xref ref-type="bibr" rid="article-24379.r3">[3]</xref>&#x000a0;Silymarin alone or silymarin combination with benzylpenicillin has been used in mushroom toxicity, but their efficacy has not yet been well studied.<xref ref-type="bibr" rid="article-24379.r23">[23]</xref>&#x000a0;In patients with cholestasis, ursodeoxycholic acid can be tried.<xref ref-type="bibr" rid="article-24379.r11">[11]</xref>&#x000a0;Antihistamines can&#x000a0;be used in case of pruritis.<xref ref-type="bibr" rid="article-24379.r14">[14]</xref>&#x000a0;Patients should be followed until&#x000a0;the resolution of symptoms and normalization of labs.<xref ref-type="bibr" rid="article-24379.r14">[14]</xref></p>
      </sec>
      <sec id="article-24379.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The diagnosis of&#x000a0;drug-induced liver injury&#x000a0;is a challenge because it can mimic any form of liver disease.<xref ref-type="bibr" rid="article-24379.r20">[20]</xref>&#x000a0;Exclusion of other possible&#x000a0;causes is important for diagnosis depending upon the pattern of liver injury.<xref ref-type="bibr" rid="article-24379.r12">[12]</xref>&#x000a0;Drug-induced liver injury&#x000a0;presents with an elevation of liver tests, which has numerous causes. All causes of hepatitis-like viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, and autoimmune hepatitis should be ruled out. Causes of cholestasis like biliary obstruction, primary biliary cirrhosis, and&#x000a0;primary sclerosing cholangitis should be considered when evaluating a patient.</p>
      </sec>
      <sec id="article-24379.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Most of the patients of&#x000a0;drug-induced liver injury&#x000a0;have a favorable prognosis.<xref ref-type="bibr" rid="article-24379.r3">[3]</xref>&#x000a0;Some patients have prolonged cholestasis even after the offending drug is withdrawn.<xref ref-type="bibr" rid="article-24379.r24">[24]</xref>&#x000a0;It will generally&#x000a0;resolve 3 to 12 months after withdrawal of the offending drug, but some patients have prolonged course and may develop vanishing bile duct syndrome and cholestatic cirrhosis, which have a poor prognosis.<xref ref-type="bibr" rid="article-24379.r3">[3]</xref>&#x000a0;The AST and bilirubin levels signify prognosis in terms of death and liver transplants.<xref ref-type="bibr" rid="article-24379.r25">[25]</xref>&#x000a0;Drug-induced liver injury&#x000a0;can cause chronic liver disease and the risk&#x000a0;usually&#x000a0;increases with cholestatic or mixed type compared to hepatocellular type.<xref ref-type="bibr" rid="article-24379.r26">[26]</xref></p>
      </sec>
      <sec id="article-24379.s12" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Acute Respiratory failure&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Acute liver failure&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Acute renal failure&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Severe metabolic acidosis&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24379.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Intensive care and consideration of&#x000a0;transfer&#x000a0;to advanced centers should be done in case of advanced disease.<xref ref-type="bibr" rid="article-24379.r11">[11]</xref></p>
      </sec>
      <sec id="article-24379.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Many of the herbal supplements, dietary supplements and other over the counter medications are often associated with liver injury which can lead to complications especially in patients with underlying liver disease. It is important to discuss with your primary care provider before starting on any herbal or dietary supplements. It is also important to go over the medications you are taking with you doctor to see if the supplements have interactions with the medications you are taking which ma lead to serious liver injury.&#x000a0;</p>
      </sec>
      <sec id="article-24379.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Drug-induced liver injury is an uncommon but important form of liver disease. When evaluating a patient for liver disease,&#x000a0;drug-induced liver injury&#x000a0;must always be considered as a possible&#x000a0;cause of liver disease as it&#x000a0;can be severe and even fatal. It can present in a pattern similar to acute hepatitis, biliary obstruction, chronic hepatitis, acute liver disease or fatty liver disease. Drug-induced liver injury&#x000a0;is usually reversible, and the first step in its management is discontinuing the drug. However,&#x000a0;drug-induced liver injury&#x000a0;is a challenging form of liver disease because of the ever increasing number of drugs used in medical care. Hundreds of drugs have been implicated as the cause. Many of the herbal supplements, dietary supplements and other over the counter medications are often underreported. A lot of research in this field is being undertaken, and there is scope for more.</p>
      </sec>
      <sec id="article-24379.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Drug-induced liver injury&#x000a0;can be prevented by educating patients by the clinician once starting them on hepatotoxic drugs and warning them about possible side effects. Clinical judgment on the part of clinician and balancing risks versus benefits when starting patients on drugs with the potential to be hepatotoxic are needed. The warnings about the possible presentations of&#x000a0;drug-induced liver injury&#x000a0;should be&#x000a0;clearly&#x000a0;stated on the medication. It also involves reporting&#x000a0;drugs that are suspected to cause liver toxicity&#x000a0;as well as regulatory bodies like FDA to take appropriate steps to withdraw the drugs from the market based on data. The National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health has developed Drug-Induced Liver Injury Network, which constitutes 6 university hospitals working to collect and analyze data. (Level V)</p>
      </sec>
      <sec id="article-24379.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24379&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24379">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/liver-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24379">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24379/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24379">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24379.s18">
        <title>References</title>
        <ref id="article-24379.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alempijevic</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zec</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Milosavljevic</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced liver injury: Do we know everything?</article-title>
            <source>World J Hepatol</source>
            <year>2017</year>
            <month>Apr</month>
            <day>08</day>
            <volume>9</volume>
            <issue>10</issue>
            <fpage>491</fpage>
            <page-range>491-502</page-range>
            <pub-id pub-id-type="pmid">28443154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ju</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced liver injury.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2010</year>
            <issue>196</issue>
            <fpage>3</fpage>
            <page-range>3-27</page-range>
            <pub-id pub-id-type="pmid">20020257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cong</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Duan</surname>
                <given-names>ZP</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>QC</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>XQ</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Nan</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CQ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Zhuang</surname>
                <given-names>H</given-names>
              </name>
              <collab>Drug-induced Liver Injury (DILI) Study Group</collab>
              <collab>Chinese Society of Hepatology (CSH)</collab>
              <collab>Chinese Medical Association (CMA)</collab>
            </person-group>
            <article-title>CSH guidelines for the diagnosis and treatment of drug-induced liver injury.</article-title>
            <source>Hepatol Int</source>
            <year>2017</year>
            <month>May</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>221</fpage>
            <page-range>221-241</page-range>
            <pub-id pub-id-type="pmid">28405790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holubek</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Kalman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study.</article-title>
            <source>Hepatology</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>880; author reply 882</fpage>
            <pub-id pub-id-type="pmid">16557558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galan</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Potts</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected].</article-title>
            <source>J Clin Gastroenterol</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <page-range>64-7</page-range>
            <pub-id pub-id-type="pmid">15599214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrade</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lucena</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pelaez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pachkoria</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Ruiz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Mu&#x000f1;oz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Grande</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pizarro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dur&#x000e1;n</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Jim&#x000e9;nez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rodrigo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Romero-Gomez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Planas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Borras</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salmer&#x000f3;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martin-Vivaldi</surname>
                <given-names>R</given-names>
              </name>
              <collab>Spanish Group for the Study of Drug-Induced Liver Disease</collab>
            </person-group>
            <article-title>Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.</article-title>
            <source>Gastroenterology</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>129</volume>
            <issue>2</issue>
            <fpage>512</fpage>
            <page-range>512-21</page-range>
            <pub-id pub-id-type="pmid">16083708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bunchorntavakul</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Review article: herbal and dietary supplement hepatotoxicity.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-17</page-range>
            <pub-id pub-id-type="pmid">23121117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ye</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez Del Moral</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Naves</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cubero</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Dissecting the molecular pathophysiology of drug-induced liver injury.</article-title>
            <source>World J Gastroenterol</source>
            <year>2018</year>
            <month>Apr</month>
            <day>07</day>
            <volume>24</volume>
            <issue>13</issue>
            <fpage>1373</fpage>
            <page-range>1373-1385</page-range>
            <pub-id pub-id-type="pmid">29632419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aleo</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Swiss</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bonin</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Potter</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Will</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.</article-title>
            <source>Hepatology</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>60</volume>
            <issue>3</issue>
            <fpage>1015</fpage>
            <page-range>1015-22</page-range>
            <pub-id pub-id-type="pmid">24799086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larrey</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and individual susceptibility to adverse drug reactions affecting the liver.</article-title>
            <source>Semin Liver Dis</source>
            <year>2002</year>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>145</fpage>
            <page-range>145-55</page-range>
            <pub-id pub-id-type="pmid">12016546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devarbhavi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>An Update on Drug-induced Liver Injury.</article-title>
            <source>J Clin Exp Hepatol</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>247</fpage>
            <page-range>247-59</page-range>
            <pub-id pub-id-type="pmid">25755441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tajiri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Practical guidelines for diagnosis and early management of drug-induced liver injury.</article-title>
            <source>World J Gastroenterol</source>
            <year>2008</year>
            <month>Nov</month>
            <day>28</day>
            <volume>14</volume>
            <issue>44</issue>
            <fpage>6774</fpage>
            <page-range>6774-85</page-range>
            <pub-id pub-id-type="pmid">19058303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chalasani</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Bonkovsky</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>RJ</given-names>
              </name>
              <collab>Practice Parameters Committee of the American College of Gastroenterology</collab>
            </person-group>
            <article-title>ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>109</volume>
            <issue>7</issue>
            <fpage>950</fpage>
            <page-range>950-66; quiz 967</page-range>
            <pub-id pub-id-type="pmid">24935270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamashita</surname>
                <given-names>YI</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chikamoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baba</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Idiosyncratic drug-induced liver injury: A short review.</article-title>
            <source>Hepatol Commun</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>1</volume>
            <issue>6</issue>
            <fpage>494</fpage>
            <page-range>494-500</page-range>
            <pub-id pub-id-type="pmid">29404475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pauli-Magnus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Hepatobiliary transporters and drug-induced cholestasis.</article-title>
            <source>Hepatology</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>778</fpage>
            <page-range>778-87</page-range>
            <pub-id pub-id-type="pmid">17006912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ouyang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thung</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Histopathologic manifestations of drug-induced hepatotoxicity.</article-title>
            <source>Clin Liver Dis</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>547</fpage>
            <page-range>547-64, vii-viii</page-range>
            <pub-id pub-id-type="pmid">24099017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a Rodr&#x000ed;guez</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Ruig&#x000f3;mez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jick</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom.</article-title>
            <source>Pharmacotherapy</source>
            <year>1997</year>
            <season>Jul-Aug</season>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>721</fpage>
            <page-range>721-8</page-range>
            <pub-id pub-id-type="pmid">9250549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katarey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced liver injury.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>Suppl 6</issue>
            <fpage>s104</fpage>
            <page-range>s104-s109</page-range>
            <pub-id pub-id-type="pmid">27956449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aithal</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Larrey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Molokhia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Takikawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Wilke</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Avigan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaplowitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bjornsson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Case definition and phenotype standardization in drug-induced liver injury.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>89</volume>
            <issue>6</issue>
            <fpage>806</fpage>
            <page-range>806-15</page-range>
            <pub-id pub-id-type="pmid">21544079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gayam</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Khalid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hossain</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Dahal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garlapati</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mandal</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Sangha</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Drug-Induced Liver Injury: An Institutional Case Series and Review of Literature.</article-title>
            <source>J Investig Med High Impact Case Rep</source>
            <year>2018</year>
            <season>Jan-Dec</season>
            <volume>6</volume>
            <fpage>2324709618761754</fpage>
            <pub-id pub-id-type="pmid">29568780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Hynan</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Rossaro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Stravitz</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Davern</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>McCashland</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Reisch</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Robuck</surname>
                <given-names>PR</given-names>
              </name>
              <collab>Acute Liver Failure Study Group</collab>
            </person-group>
            <article-title>Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure.</article-title>
            <source>Gastroenterology</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>137</volume>
            <issue>3</issue>
            <fpage>856</fpage>
            <page-range>856-64, 864.e1</page-range>
            <pub-id pub-id-type="pmid">19524577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giannattasio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D'Ambrosi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Volpicelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iorio</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Steroid therapy for a case of severe drug-induced cholestasis.</article-title>
            <source>Ann Pharmacother</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>1196</fpage>
            <page-range>1196-9</page-range>
            <pub-id pub-id-type="pmid">16720710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Enjalbert</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rapior</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nouguier-Soul&#x000e9;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guillon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amouroux</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cabot</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Treatment of amatoxin poisoning: 20-year retrospective analysis.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>2002</year>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>715</fpage>
            <page-range>715-57</page-range>
            <pub-id pub-id-type="pmid">12475187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Degott</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Feldmann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Larrey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Durand-Schneider</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Grange</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Machayekhi</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Moreau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Potet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Benhamou</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia.</article-title>
            <source>Hepatology</source>
            <year>1992</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>244</fpage>
            <page-range>244-51</page-range>
            <pub-id pub-id-type="pmid">1735527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bj&#x000f6;rnsson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Outcome and prognostic markers in severe drug-induced liver disease.</article-title>
            <source>Hepatology</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>481</fpage>
            <page-range>481-9</page-range>
            <pub-id pub-id-type="pmid">16025496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24379.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrade</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lucena</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Kaplowitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Mu&#x00146;oz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Borraz</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pachkoria</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Cort&#x000e9;s</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pelaez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rodrigo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dur&#x000e1;n</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Planas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barriocanal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guarner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Romero-Gomez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mu&#x00146;oz-Yag&#x000fc;e</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Salmer&#x000f3;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hidalgo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry.</article-title>
            <source>Hepatology</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>1581</fpage>
            <page-range>1581-8</page-range>
            <pub-id pub-id-type="pmid">17133470</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
